PubMed Central

Efficacy and safety of lumateperone for bipolar depression and schizophrenia: a systematic review and meta-analysis - PMC

High trust

The International Journal of Neuropsychopharmacology, 2024 Cited by 10 papers doi:10.1093/ijnp/pyae052

Read the original →

What this article backs

In its own words

Lumateperone is a novel approved APD by the FDA for treating adults with schizophrenia or bipolar I and II depression, either as monotherapy or in conjunction with lithium or valproate.
PubMed Central

Corroborated by

More from PubMed Central